basic and diluted 146,296 79,709 123,634 78,672
Biodesix, Inc.
Reconciliation of Net Loss to Adjusted EBITDA (unaudited)
(in thousands)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------- ---------------------
2024 2023 2024 2023
-------- ---------- -------- ----------
Net loss $(10,258) $ (10,949) $(34,680) $ (43,007)
Interest
expense 2,041 2,386 6,506 7,207
Depreciation
and
amortization 1,492 782 4,324 2,351
Share-based
compensation
expense 1,515 954 5,373 4,292
Loss on
extinguishment
of liabilities -- -- 248 --
COVID-19
Revenue -- -- -- (13)
COVID-19 Direct
costs and
expenses -- -- -- 1
Change in fair
value of
warrant
liability,
net -- 1,393 -- 1,332
Other expense
(income), net (374) (2) 77 (4)
------- --------- ------- ---------
Adjusted EBITDA $ (5,584) $ (5,436) $(18,152) $ (27,841)
======= ========= ======= =========
(END) Dow Jones Newswires
November 01, 2024 06:00 ET (10:00 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。